Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Moderately to Severely Active Crohn's Disease

NCT00265122 is registered in ClinicalTrials.gov with Centocor, Inc. as lead sponsor.

NCT NCT00265122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00265122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Moderately to Severely Active Crohn's Disease
Lead sponsor
Centocor, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2004
Completion date
October 31, 2006
Enrollment
131 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease